Last updated: November 11, 2026
Gadoversetamide, marketed as OptiMARK, is a legacy gadolinium-based contrast agent for magnetic resonance imaging. Its commercial position has deteriorated because newer macrocyclic agents gained share, regulatory scrutiny increased over gadolinium retention, and the product lost meaningful exclusivity years ago. The FDA record identifies OptiMARK as discontinued, while no material current U.S. patent barrier appears to protect commercial entry. Product-level revenue is not separately disclosed by its historical sponsor, limiting precise valuation of the asset.
What is gadoversetamide and how is it used?
Gadoversetamide is a nonionic, linear gadolinium chelate administered intravenously for contrast-enhanced MRI. OptiMARK was approved in the United States for use in adults and pediatric patients at least two years old to improve the visualization of central nervous system, liver and other structures during MRI examinations.[1]
| Attribute |
Gadoversetamide |
| Brand |
OptiMARK |
| Active ingredient |
Gadoversetamide |
| Drug class |
Gadolinium-based contrast agent |
| Molecular design |
Linear, nonionic chelate |
| Administration |
Intravenous |
| U.S. regulatory application |
NDA 21-135 |
| Primary use |
Contrast-enhanced MRI |
| Historical sponsor |
Mallinckrodt and predecessor organizations |
| Current U.S. status |
FDA record identifies the product as discontinued |
| Exclusivity position |
Original regulatory exclusivity expired |
| Orange Book risk |
No material current patent barrier identified in the public FDA record |
Gadoversetamide is a diagnostic product rather than a therapeutic drug. Its demand depends on MRI procedure volumes, hospital purchasing contracts, radiology utilization and the availability of competing contrast agents.
When did gadoversetamide lose exclusivity?
Gadoversetamide lost meaningful market exclusivity long before the current period. The product was approved in 1999, and its original five-year new chemical entity exclusivity expired in 2004.[1] Any patent protection associated with the original product and formulation would also have expired or become commercially immaterial by the 2020s.
The practical consequence is that market access is determined less by patent exclusivity than by:
- Regulatory approval and manufacturing capability.
- Hospital and radiology-group formularies.
- Supply reliability.
- Purchasing contracts.
- Contrast-agent safety preferences.
- The cost of switching imaging protocols.
For an injectable contrast agent, the absence of an active patent does not automatically produce immediate generic competition. Manufacturers still must validate sterile manufacturing, establish supply chains for the chelate and gadolinium raw materials, obtain FDA approval, and meet institutional purchasing requirements.
What is the FDA and Orange Book status of OptiMARK?
FDA records identify OptiMARK under NDA 21-135 and show the product as discontinued in the U.S. regulatory database.[1] The discontinuation status indicates that the branded product is no longer being actively marketed as a conventional U.S. commercial product. It does not by itself establish that the drug was withdrawn for safety or efficacy reasons.
The Orange Book is relevant because it records approved drug products, patent listings and regulatory exclusivity. Gadoversetamide’s original exclusivity period has expired, and no current Orange Book patent position appears to create a meaningful barrier to an approved generic or follow-on supplier.[2]
FDA regulatory milestones
| Milestone |
Timing |
| U.S. approval of OptiMARK |
1999 |
| New chemical entity exclusivity |
Expired in 2004 |
| Label evolution |
Included renal-risk and gadolinium-safety warnings |
| U.S. commercial status |
Discontinued in the FDA database |
| Current patent-based exclusivity |
No material active barrier identified |
The FDA has imposed class-wide safety controls on gadolinium-based contrast agents, including warnings concerning nephrogenic systemic fibrosis in patients with severe renal impairment and gadolinium retention in the body.[3] These controls affect product selection across the entire GBCA market rather than gadoversetamide alone.
What patents protect gadoversetamide?
The current commercial patent estate for gadoversetamide appears weak or exhausted. The original composition, chelation and product patents associated with the development of OptiMARK are historical assets, not a present-day source of market exclusivity.
Patent categories relevant to gadoversetamide
| Patent category |
Commercial relevance today |
| Gadolinium-chelate composition patents |
Historical; original terms have expired |
| OptiMARK formulation patents |
Historical; no current material exclusivity identified |
| Manufacturing-process patents |
Could protect a specific process, but would not block all gadoversetamide products |
| Method-of-use patents |
Limited value because MRI contrast use is established and broad |
| Device or vial patents |
Potentially narrow and commercially insufficient without product protection |
| Orange Book-listed patents |
No material current barrier identified in the public record |
A process patent could still create a narrow manufacturing constraint if it covered a particular purification, chelation or formulation step. That type of claim would not necessarily prevent a competitor from developing a different process. The absence of a strong composition patent makes such a strategy less effective as a standalone defense.
Are there Paragraph IV challenges to gadoversetamide?
No significant publicly documented Paragraph IV litigation involving gadoversetamide appears to have driven the U.S. market. The lack of major litigation is consistent with the product's limited current commercial value and discontinued branded status.
A Paragraph IV filing requires an ANDA applicant to certify that a listed patent is invalid, unenforceable or will not be infringed. Because gadoversetamide's principal exclusivity periods are historical and no material active Orange Book barrier is apparent, a new entrant would have had limited incentive to incur high-value patent litigation costs.
The more relevant commercial question is whether a generic manufacturer would pursue a new ANDA for a discontinued product. That decision would depend on:
- Remaining MRI contrast demand.
- Number of competing GBCAs.
- Hospital willingness to add a low-volume product.
- Cost of sterile injectable manufacturing.
- Availability of substitute agents.
- Pricing pressure after approval.
How strong is the gadoversetamide patent estate?
The patent estate is weak from a current investment perspective. It may have supported the original launch and early commercialization, but it does not appear to provide a durable barrier against a technically capable competitor.
Strength assessment
| Factor |
Assessment |
| Composition patent life |
Exhausted |
| Regulatory exclusivity |
Exhausted |
| Formulation protection |
Limited current value |
| Method-of-use protection |
Weak |
| Manufacturing know-how |
Potentially relevant but not a broad market block |
| Litigation leverage |
Low |
| Generic entry deterrence |
Low to moderate, driven mainly by economics |
| Commercial defensibility |
Low |
The strongest remaining barrier is likely operational rather than legal. A supplier must manufacture a sterile injectable product consistently, qualify raw materials, meet FDA quality requirements and maintain distribution. Those requirements can deter marginal entrants, but they do not support premium pricing comparable to a patented pharmaceutical.
What formulation patents protect gadoversetamide?
Gadoversetamide is supplied as an injectable solution. Formulation protection historically could have covered concentration, excipient selection, pH, stability, container closure or manufacturing controls. Those claims typically have narrower scope than the active-ingredient patent and are vulnerable to design-around strategies.
A competitor could potentially avoid a formulation claim by changing:
- Excipient composition.
- Buffer system.
- Container configuration.
- Manufacturing sequence.
- Concentration or presentation.
- Sterilization and filling process.
The economic value of a formulation patent would therefore depend on claim breadth and whether the formulation was necessary to achieve acceptable stability and injectability. There is no public indication that a current formulation patent materially protects OptiMARK in the United States.
How does gadoversetamide compare with competing MRI contrast agents?
Gadoversetamide competes with both linear and macrocyclic GBCAs. Major alternatives include gadobutrol, gadoterate meglumine, gadoteridol, gadopentetate dimeglumine and gadobenate dimeglumine. Several competing products are supported by stronger commercial infrastructure, broader institutional adoption or macrocyclic chemistry.
| Agent |
Representative brand |
Structural class |
Competitive position |
| Gadoversetamide |
OptiMARK |
Linear, nonionic |
Legacy, discontinued U.S. product |
| Gadobutrol |
Gadavist |
Macrocyclic, nonionic |
Strong modern competitor |
| Gadoterate meglumine |
Dotarem |
Macrocyclic, ionic |
Broad hospital and radiology adoption |
| Gadoteridol |
ProHance |
Macrocyclic, nonionic |
Established alternative |
| Gadobenate dimeglumine |
MultiHance |
Linear, ionic |
Specialty and organ-specific use |
| Gadopentetate dimeglumine |
Magnevist |
Linear, ionic |
Older product with declining relevance |
Macrocyclic agents generally have greater thermodynamic and kinetic stability than linear agents. That distinction became commercially important as regulators and radiologists focused on gadolinium retention and long-term exposure. The FDA concluded that all GBCAs may leave trace amounts of gadolinium in the body, while macrocyclic agents generally retain less than linear agents.[3]
This safety differentiation did not necessarily make gadoversetamide unusable, but it reduced its strategic attractiveness where hospitals could substitute a macrocyclic product without compromising workflow.
What factors drove the gadoversetamide market decline?
The market decline reflects a combination of product age, competition and regulatory preference.
Competitive substitution
The MRI contrast market includes multiple approved agents with overlapping indications. Hospitals can substitute among products based on price, supply and institutional policy. Gadoversetamide therefore lacked the protected demand characteristic of a single-source specialty product.
Gadolinium-retention concerns
The FDA required class-wide label changes in 2017 to address gadolinium retention.[3] The agency required medication guides for patients and emphasized that retention was higher with linear agents than with macrocyclic agents. This created a commercial headwind for older linear products.
Hospital purchasing pressure
Contrast agents are commonly purchased through group purchasing organizations and hospital contracts. Price concessions, supply commitments and bundled purchasing influence share. A discontinued brand with limited differentiation is poorly positioned in this environment.
Manufacturing economics
Gadoversetamide requires sterile injectable production and quality controls. A low-volume product can become uneconomic if manufacturing runs are small, raw-material costs rise or the sponsor cannot maintain an efficient filling and distribution network.
Portfolio rationalization
Large pharmaceutical suppliers have narrowed portfolios around higher-volume diagnostic agents. A legacy contrast agent with limited growth, no patent runway and substantial quality obligations is a candidate for discontinuation or deprioritization.
What was the financial trajectory of gadoversetamide?
Public filings do not provide a reliable standalone revenue series for OptiMARK. Mallinckrodt and predecessor companies reported broader business segments, and gadoversetamide revenue was not consistently disclosed as a separate line item. The financial trajectory must therefore be inferred from regulatory and market indicators rather than product-level sales data.
Commercial trajectory
| Period |
Financial interpretation |
| 1999 to mid-2000s |
Launch and protected branded revenue |
| Late 2000s |
Mature-product phase with broader GBCA competition |
| 2010s |
Declining differentiation and increasing safety pressure |
| Late 2010s to early 2020s |
Likely lower-volume product with limited pricing power |
| Current U.S. status |
Discontinued, with no visible branded growth platform |
Revenue exposure for the historical sponsor was likely modest relative to its larger pharmaceutical and specialty-product portfolio by the end of the product life cycle. The absence of separately reported OptiMARK revenue prevents a defensible estimate of peak sales, current sales or the product's contribution to corporate earnings.
The discontinuation also implies that future financial value is limited. Potential value could arise from an authorized generic, an out-licensed manufacturing arrangement or sales in a jurisdiction where the product remains registered. No major current licensing transaction or commercial revitalization program for gadoversetamide is evident in the public record.
Which companies are challenging or replacing gadoversetamide?
No major active patent challenger is publicly associated with the U.S. OptiMARK market. Competitive pressure comes from manufacturers of alternative GBCAs rather than from a single named Paragraph IV challenger.
Relevant competitors include:
- Bayer, with Gadavist.
- Guerbet, with Dotarem.
- Bracco, with ProHance and MultiHance.
- GE HealthCare, with Omniscan and related imaging products.
- Generic manufacturers supplying older gadolinium agents in selected markets.
These companies compete through product availability, hospital contracting, radiology protocols, macrocyclic chemistry, safety positioning and global distribution.
What generic launch risks exist for gadoversetamide?
A generic launch would face low patent risk but meaningful commercial risk. The product is technically approvable in principle, yet the market may not support the cost of development and launch.
Generic entry scenarios
| Scenario |
Probability implication |
Market effect |
| No entrant |
Commercial demand remains too small |
Product remains unavailable or niche |
| Single generic entrant |
Moderate economic possibility |
Low-price supply for selected institutions |
| Multiple generic entrants |
Less attractive |
Rapid price erosion |
| Authorized generic or licensed restart |
Potentially efficient |
Limited-volume availability |
| Non-U.S. supply only |
Jurisdiction-specific |
No meaningful U.S. impact |
The main barriers are not patents. They are sterile manufacturing economics, regulatory filing costs, limited differentiation and substitution by macrocyclic agents. A generic entrant could obtain approval yet fail to establish durable market share.
What litigation and settlement agreements affect gadoversetamide?
No major current U.S. patent litigation or settlement agreement appears to affect gadoversetamide commercialization. The lack of a high-value litigation record reflects the product's expired exclusivity and limited remaining market opportunity.
Any historical disputes would need to be evaluated against the relevant patent family, jurisdiction, claim scope and settlement terms. They do not appear to create a current nationwide restriction on generic development.
What is the geographic coverage of gadoversetamide?
The commercial status of gadoversetamide is jurisdiction-specific. U.S. discontinuation does not automatically establish withdrawal in every foreign market. Registration, supply and marketing status may differ across Europe, Asia-Pacific, Latin America and other regions.
The product's global opportunity is constrained by the same factors that affect the U.S. market:
- Preference for macrocyclic GBCAs.
- Country-specific gadolinium-retention guidance.
- Local generic competition.
- Hospital procurement systems.
- Availability of modern substitutes.
- Cost of maintaining multiple regulatory registrations.
A regional relaunch would require current quality documentation, regulatory compliance, local pharmacovigilance and a credible supply plan.
What manufacturing and intellectual-property barriers remain?
The principal remaining barriers are manufacturing and quality-related:
- Sterile injectable production.
- Control of elemental impurities.
- Consistent chelation and purification.
- Stability through shelf life.
- Container-closure integrity.
- Validated analytical methods.
- Compliance with current GMP requirements.
- Reliable supply of gadolinium-containing raw materials.
These barriers can limit the number of suppliers but do not create the same competitive protection as an unexpired composition patent. A company evaluating the asset should treat gadoversetamide as a low-margin, operationally intensive generic diagnostic product rather than a protected specialty pharmaceutical.
Key Takeaways
- Gadoversetamide, marketed as OptiMARK, is an older linear, nonionic GBCA for contrast-enhanced MRI.
- The product was approved in the United States in 1999, and its five-year new chemical entity exclusivity expired in 2004.
- FDA records identify OptiMARK as discontinued in the U.S.
- No material current Orange Book patent barrier is apparent.
- No significant active Paragraph IV litigation or settlement is publicly associated with the product.
- Macrocyclic agents such as Gadavist, Dotarem and ProHance weakened gadoversetamide's commercial position.
- Gadolinium-retention warnings created an additional disadvantage for older linear agents.
- Product-level revenue and profit were not separately disclosed in a way that supports a reliable financial forecast.
- Future value is more likely to depend on low-cost sterile manufacturing or regional supply than on patent exclusivity.
- Generic entry risk is legally high but commercially limited by low demand, strong substitutes and manufacturing economics.
FAQs About Gadoversetamide
Is gadoversetamide still sold in the United States?
The FDA regulatory record identifies OptiMARK, the U.S. gadoversetamide product, as discontinued. Current U.S. commercial availability is therefore limited or absent.
Does gadoversetamide have an active U.S. patent?
No material active U.S. patent barrier is apparent in the current public FDA Orange Book record. Historical composition and product patents have no meaningful remaining exclusivity.
Is gadoversetamide a macrocyclic gadolinium contrast agent?
No. Gadoversetamide is a linear, nonionic gadolinium chelate. Macrocyclic alternatives generally have greater chelate stability.
Could a generic manufacturer relaunch gadoversetamide?
Yes, in principle, subject to FDA approval and compliant sterile manufacturing. Commercial success would be uncertain because hospitals can substitute several established GBCAs.
Why did gadoversetamide lose market share?
The main causes were competition from newer macrocyclic agents, concerns about gadolinium retention, limited product differentiation, hospital price pressure and the economics of maintaining an older sterile injectable product.
References
-
U.S. Food and Drug Administration. (1999). OptiMARK (gadoversetamide injection) prescribing information and NDA 21-135. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2017). FDA warns that gadolinium-based contrast agents are retained in the body; requires new class warnings. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-gadolinium-based-contrast-agents-are-retained-body-requires-new-class-warnings
